Foundation Medicine Joins the WIN Consortium in Personalized Cancer Medicine
Posted: Tuesday, March 27, 2012
Foundation Medicine, Cambridge, MA, joins WIN Consortium (Paris) and becomes member of the Worldwide Innovative Networking in personalized cancer medicine
WIN Consortium, is a network of 22 academic institutions and industries across the globe, initiated by Cancer Institute Gustave Roussy (IGR), France and University of Texas MD Anderson Cancer Center, USA (MDACC), focusing on biomarker-driven therapeutic clinical trials conducted worldwide.
About Foundation Medicine
Foundation Medicine is dedicated to improving cancer care through the development of comprehensive NGS cancer diagnostics that, identify and interpret an ever-growing set of actionable genomic alterations. Founding advisors are world leaders in genome technology, cancer biology and medical oncology. Please visit the company’s website at www.foundationmedicine.com.
Contacts
WIN Consortium:
Vladimir Lazar, Chief Operating Officer,
vladimir.lazar@winconsortium.org
Catherine Bresson, Director of operations, Catherine.bresson@@winconsortium.org
Foundation Medicine:
Gary Palmer, Vice President,
gpalmer@foundationmedicine.com
Disclaimers
(*) This program has the ASCO, ESMO, UICC and INCa approval for quality of educational content. The endorsement does not constitute medical advice. Health care providers should exercise their own independent medical judgment.
(*)ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.